Módszerek összehasonlítása
Tekintse át a kiválasztott módszereket egymás mellett; az eltérő sorok kiemelve jelennek meg.
| Bayesiánus Randomizált Klinikai Vizsgálat× | II. fázisú klinikai vizsgálat – Korai hatékonysági és dózisértékelés× | |
|---|---|---|
| Tudományterület | Epidemiológia | Epidemiológia |
| Módszercsalád | Process / pipeline | Process / pipeline |
| Keletkezés éve≠ | 1980s–2000s (formal methodology consolidated ~2004–2006) | 1960s–1970s (formalised in US federal drug regulation) |
| Megalkotó≠ | Donald A. Berry and David J. Spiegelhalter (applied Bayesian inference formally to RCT design) | U.S. Food and Drug Administration / ICH E8 guidelines (institutionalised framework) |
| Típus≠ | Randomized experimental study with Bayesian inference | Interventional clinical study design |
| Alapmű≠ | Spiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley. ISBN: 978-0471499756 | Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185392 |
| Alternatív nevek | Bayesian RCT, Bayesian adaptive trial, Bayesian clinical trial design, BRCT | Phase 2 trial, Phase II study, early efficacy trial, proof-of-concept trial |
| Kapcsolódó≠ | 5 | 6 |
| Összefoglaló≠ | A Bayesian randomized clinical trial (Bayesian RCT) combines the rigour of random treatment allocation with Bayesian statistical inference, allowing researchers to incorporate prior evidence and update beliefs continuously as trial data accumulate. Unlike the classical frequentist RCT, it yields direct probability statements about treatment effects and supports pre-specified adaptive stopping rules based on posterior probabilities. | A Phase II clinical trial is the second stage in the drug or intervention development pipeline, conducted after Phase I safety testing. Its primary goal is to assess whether the intervention shows preliminary efficacy signals in a relevant patient population at the dose established in Phase I, while continuing to characterise the safety and tolerability profile. Phase II trials are generally smaller than Phase III confirmatory trials and serve as critical go/no-go decision points before large-scale investment. |
| ScholarGateAdatkészlet ↗ |
|
|